BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more
BioRestorative Therapies Inc (BRTX) - Net Assets
Latest net assets as of September 2025: $2.21 Million USD
Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has net assets worth $2.21 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.64 Million) and total liabilities ($3.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.21 Million |
| % of Total Assets | 39.11% |
| Annual Growth Rate | 0.88% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 41.75 |
BioRestorative Therapies Inc - Net Assets Trend (2009–2024)
This chart illustrates how BioRestorative Therapies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioRestorative Therapies Inc (2009–2024)
The table below shows the annual net assets of BioRestorative Therapies Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $8.53 Million | -14.72% |
| 2023-12-31 | $10.00 Million | -2.78% |
| 2022-12-31 | $10.29 Million | -52.35% |
| 2021-12-31 | $21.60 Million | +1722.01% |
| 2020-12-31 | $-1.33 Million | +89.58% |
| 2019-12-31 | $-12.78 Million | -47.85% |
| 2018-12-31 | $-8.64 Million | -26.39% |
| 2017-12-31 | $-6.84 Million | -36.72% |
| 2016-12-31 | $-5.00 Million | -27.93% |
| 2015-12-31 | $-3.91 Million | +43.26% |
| 2014-12-31 | $-6.89 Million | -3.04% |
| 2013-12-31 | $-6.69 Million | -30.02% |
| 2012-12-31 | $-5.14 Million | -39.48% |
| 2011-12-31 | $-3.69 Million | -395.34% |
| 2010-12-31 | $-744.22K | -109.95% |
| 2009-12-31 | $7.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioRestorative Therapies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15567871500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $692.00 | 0.01% |
| Other Components | $164.21 Million | 1924.77% |
| Total Equity | $8.53 Million | 100.00% |
BioRestorative Therapies Inc Competitors by Market Cap
The table below lists competitors of BioRestorative Therapies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ICNP
PINK:ICNP
|
$1.51 Million |
|
STEEL DYNAMICS - Dusseldorf Stock Exchang
DU:SD5
|
$1.51 Million |
|
PT BK PANIN DU. SY. RP100
F:2PS
|
$1.51 Million |
|
Pure Foods Tasmania Ltd
AU:PFT
|
$1.52 Million |
|
BSF Enterprise Plc
PINK:BSFAF
|
$1.51 Million |
|
Mystic Holdings Inc.
OTCQB:MSTH
|
$1.51 Million |
|
C.H.ROBINSON WLDWDE - Dusseldorf Stock Exchang
DU:CH1A
|
$1.51 Million |
|
Orphazyme A/S
PINK:OZYMF
|
$1.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioRestorative Therapies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,004,375 to 8,531,393, a change of -1,472,982 (-14.7%).
- Net loss of 8,979,381 reduced equity.
- Dividend payments of 623,801 reduced retained earnings.
- Other factors increased equity by 8,130,200.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.98 Million | -105.25% |
| Dividends Paid | $623.80K | -7.31% |
| Other Changes | $8.13 Million | +95.3% |
| Total Change | $- | -14.72% |
Book Value vs Market Value Analysis
This analysis compares BioRestorative Therapies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $-695.53 | $0.25 | x |
| 2011-12-31 | $-24413.23 | $0.25 | x |
| 2012-12-31 | $-27643.51 | $0.25 | x |
| 2013-12-31 | $-28088.53 | $0.25 | x |
| 2014-12-31 | $-16246.21 | $0.25 | x |
| 2015-12-31 | $-4726.07 | $0.25 | x |
| 2016-12-31 | $-4259.18 | $0.25 | x |
| 2017-12-31 | $-4474.19 | $0.25 | x |
| 2018-12-31 | $-2947.15 | $0.25 | x |
| 2019-12-31 | $-656.47 | $0.25 | x |
| 2020-12-31 | $-3.37 | $0.25 | x |
| 2021-12-31 | $18.18 | $0.25 | x |
| 2022-12-31 | $2.84 | $0.25 | x |
| 2023-12-31 | $2.37 | $0.25 | x |
| 2024-12-31 | $1.10 | $0.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioRestorative Therapies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -105.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2239.25%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.44x
- Recent ROE (-105.25%) is below the historical average (-36.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.19 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.71 Million |
| 2012 | 0.00% | -41931.63% | 0.01x | 0.00x | $-6.02 Million |
| 2013 | 0.00% | -342332.98% | 0.00x | 0.00x | $-5.08 Million |
| 2014 | 0.00% | -1343.19% | 0.25x | 0.00x | $-4.90 Million |
| 2015 | 0.00% | -1259.87% | 0.31x | 0.00x | $-7.53 Million |
| 2016 | 0.00% | -23755.44% | 0.02x | 0.00x | $-8.14 Million |
| 2017 | 0.00% | -11660.07% | 0.05x | 0.00x | $-8.76 Million |
| 2018 | 0.00% | -11277.30% | 0.09x | 0.00x | $-11.65 Million |
| 2019 | 0.00% | -11267.61% | 0.09x | 0.00x | $-13.37 Million |
| 2020 | 0.00% | -14639.85% | 0.02x | 0.00x | $-11.14 Million |
| 2021 | -205.14% | -96311.51% | 0.00x | 1.04x | $-46.46 Million |
| 2022 | -128.49% | -11036.97% | 0.01x | 1.60x | $-14.25 Million |
| 2023 | -104.13% | -7145.20% | 0.01x | 1.26x | $-11.42 Million |
| 2024 | -105.25% | -2239.25% | 0.03x | 1.44x | $-9.83 Million |
Industry Comparison
This section compares BioRestorative Therapies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioRestorative Therapies Inc (BRTX) | $2.21 Million | 0.00% | 1.56x | $1.51 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |